FDA and CMS Open the Door to AI-Integrated Diagnostics With New Guidelines and Reimbursement Codes
In Vitro Diagnostics Market size was valued at USD 85.27 billion in 2025 and is projected to grow from USD 90.84 billion in 2026 to USD 152.62 billion by 2034, registering a CAGR of 6.7%, according to Polaris Market Research. In vitro diagnostics (IVD) comprises devices and tests that analyze bodily samples such as blood, tissue and urine outside the body to diagnose diseases, detect infections and monitor treatment. Demand for tests with greater sensitivity, specificity and speed, together with the rising burden of chronic disease, is driving expansion.
Disease burden and aging fuel demand
Chronic and infectious disease burden underpins the In Vitro Diagnostics Market. WHO data cited on the page shows noncommunicable diseases cause 41 million deaths annually, or 74% of global deaths. That includes 17.9 million from cardiovascular diseases, 9.3 million from cancers, 4.1 million from chronic respiratory diseases and 2.0 million from diabetes. Early detection and monitoring improve patient outcomes and reduce costs by enabling timely intervention and preventing complications.
Aging adds structural demand. According to World Population Prospects 2022, people aged 65 and above are projected to rise from 10% of the global population in 2022 to 16% by 2050. Age-related conditions such as Alzheimer’s disease and osteoporosis require frequent monitoring and early detection, which sustains demand for advanced IVD solutions.
Technology and AI reshape testing
Molecular diagnostics, next-generation sequencing (NGS) and point-of-care testing (POCT) are transforming clinical practice. Molecular tests detect genetic and biochemical markers for earlier, more precise diagnosis. NGS enables rapid DNA and RNA sequencing for personalized medicine, and POCT delivers results at or near the patient. AI accelerates analysis of sequencing data for hereditary conditions and cancer, reduces human error, shortens turnaround times and helps laboratories manage rising volumes and workforce shortages. The FDA and CMS are introducing guidelines and reimbursement codes for AI-integrated diagnostics.
Explore The Complete Comprehensive Report Here : https://www.polarismarketresearch.com/industry-analysis/in-vitro-diagnostics-market
Segment leaders
Immunoassays held the largest technology share at 34.60% in 2025, thanks to reliability, speed and minimal sample preparation across formats such as ELISA and lateral flow assays. In July 2023, Siemens Healthineers launched the Atellica CI Analyzer, combining immunoassay and clinical chemistry testing with faster turnaround. By application, infectious diseases lead and are projected to be the fastest-growing segment, driven by COVID-19, HIV, hepatitis, influenza, sexually transmitted infections and multi-drug-resistant pathogens. In August 2022, Becton Dickinson collaborated with Accelerate Diagnostics on rapid antibiotic resistance testing.
Regional outlook
North America dominated with a 37.76% revenue share in 2025, supported by high chronic disease rates, strong test use, numerous established players and government funding. In January 2023, BD and CerTest Biotec received FDA Emergency Use Authorization for a PCR assay to detect the Mpox virus. Asia Pacific is expected to grow fastest at an 8.3% CAGR through 2034 on rising healthcare access, a growing middle class and supportive government policies. In October 2023, Fapon and Halodoc partnered to boost IVD product sales and services in Indonesia.
Constraints and opportunities
The complexity and cost of FDA approval and a lack of transparency hinder growth. Advanced tests can be costly and unevenly accessible, and maintaining accuracy across different conditions can be difficult. Advances in immunoassay technologies are expected to open lucrative opportunities over the forecast period.
Competitive landscape and developments
Key players include Abbott, Agilent Technologies, BD, bioMérieux, Bio-Rad, Charles River Laboratories, Danaher, Roche, Qiagen, Quest Diagnostics, QuidelOrtho, Siemens Healthineers, Sysmex and Thermo Fisher Scientific. In July 2024, BD and Quest Diagnostics began collaborating on companion diagnostics for cancer and other diseases. In April 2024, Agilent’s GenetiSure Dx Postnatal Assay received European IVDR Class C certification, and in January 2024 ELITechGroup launched a CE-IVDR certified GI Bacterial PLUS kit. In February 2025, ABL Diagnostics said it would commercialize UltraGene PCR tests covering more than 100 pathogens.
In Vitro Diagnostics Market growth through 2034 will be shaped by faster, more accurate tests, wider point-of-care access and AI-supported laboratory workflows. Immunoassays and infectious disease testing anchor demand today, North America leads on revenue, and Asia Pacific is set to expand fastest. Manufacturers that pair regulatory readiness with rapid, reliable and affordable testing platforms are best placed to capture the next phase of growth.
More Trending Latest Reports By Polaris Market Research:
Rare Disease Genetic Testing Market
U.S. Steel Merchant and Rebar Market
- Art
- Causes
- Crafts
- Dance
- Drinks
- Film
- Fitness
- Food
- Jogos
- Gardening
- Health
- Início
- Literature
- Music
- Networking
- Outro
- Party
- Religion
- Shopping
- Sports
- Theater
- Wellness